HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J no liability

This article was originally published in The Tan Sheet

Executive Summary

A California jury cleared McNeil Consumer & Specialty Pharmaceuticals on July 17 of liability in a lawsuit filed by 11-year-old Sabrina Brierton Johnson, who suffered Stevens-Johnson syndrome after using Children's Motrin. Johnson, who is now blind, will appeal her case, which alleges the Johnson & Johnson division failed to adequately warn on its product label that the ibuprofen in Motrin can trigger a rare allergic reaction that causes blindness and even death, according to lawyers at Greene Broillet & Wheeler, which represented the girl and her parents in the case litigated in Los Angeles Superior Court ("The Tan Sheet" June 16, 2008, p. 9)...

You may also be interested in...



Children’s Motrin Suit Seeks Compensation, New Label For Ibuprofen Product

A lawsuit that alleges Children's Motrin with ibuprofen caused a girl's blindness wants McNeil Consumer & Specialty Pharmaceuticals to clearly list all potential serious adverse reactions on the product's label and compensate the child

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Topics

UsernamePublicRestriction

Register

RS137441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel